Bile acids have been traditionally viewed as detergent molecules involved in the solubilization and absorption of lipids and lipidsoluble vitamins from the intestines. However, as a result of intensive research over the past two decades, bile acids are now viewed as endocrine signaling molecules that activate specific nuclear receptors and G-protein coupled receptors regulating nutrient metabolism in the liver and intestines. The year 2015 marks the 20-year anniversary of the cloning and discovery of farnesoid X receptor (NR4H1; FXR). FXR is a main bile acid nuclear receptor and plays an essential role in the regulation of bile acids, lipids, glucose and drug metabolism, as well as inhibiting inflammation and suppressing carcinogenesis in the liver and intestine. Bile acids also activate pregnane X receptor, constitutive androstane receptor, vitamin D receptor, G protein-coupled bile acid receptor (TGR5), and sphingosine-1-phosphate receptor 2 (S1PR2) to regulate growth and functions of hepatocytes, cholangiocytes and enterocytes. Moreover, bile acids also induce, via FXR, critical regulators of metabolism, inflammation and carcinogenesis in the liver and intestine, including small heterodimer partner (SHP) and fibroblast growth factor 15/19 (FGF15/19). The regulation of bile acid homeostasis is subject to traditional gene promoter regulation, posttranscriptional modulation and epigenetic regulation.
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Historically, bile acids have been used as medicines around the world. Identification of new signaling pathways mediated by bile acids and bile acid derivatives should result in optimizing the current standard therapy for hepatic disorders and developing novel therapeutic targets for various liver diseases and metabolic syndrome.
In this issue, we have gathered leading experts in bile acid research around the world to provide the most comprehensive and timely review of bile acids, their receptors and regulated pathways/ functions with a focus on liver and the gastrointestinal area. These in-depth reviews will provide the researchers, clinicians and pharmaceutical entrepreneurs the background knowledge for targeting bile acid-mediated signaling pathways to prevent and treat hepatic, intestinal, and metabolic disorders. 
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The sphingosine 1-phosphate receptor 2 (S1PR2), along with insulin, plays an important role in the regulation of nutrient metabolism in the liver. Following a meal, conjugated bile acids (CBAs) returning to the liver bind to S1PR2 activating both the ERK1/2 and AKT (insulin signaling pathway). Activation of the insulin signaling pathway by CBAs and insulin activates phosphoinositide-dependent protein kinase 1 (PDK1), which activates protein kinase C ζ (PKCζ). PKCζ then phosphorylates the farnesoid X receptor (FXR) allowing it to translocate to the nucleus. FXR is activated by bile acids causing the induction of a number of genes involved in bile acid metabolism and transport. Bile http://dx.doi.org/10.1016/j.apsb.2015.03.002 acids induce the gene encoding the short heterodimeric partner (SHP). SHP is a nuclear receptor, without a DNA binding domain, and functions much like a dominant-negative protein by interacting with other nuclear receptors (HNF4α, LRH-1 and others) to inhibit their functions. HNF4α is also an important regulator of nutrient metabolism in the liver. PKCζ also regulates the movement of the basolateral bile acid transporter (NTCP) and canalicular membrane transporter (BSEP) to their respective membranes. Activated AKT increases glycogen synthesis and inhibits glucose synthesis by down-regulating the genes encoding the gluconeogenic genes, PEPCK and G-6-Pase, and activating glycogen synthase activity, respectively. S1PR2 also activates nuclear sphingosine kinase 2 (SphK2) increasing the concentration of S1P in the nucleus, a powerful inhibitor of histone deacetylase 1 and 2 (HDAC 1/2). Inhibition of HDAC 1/2 allows for increased histone acetylation and increased differential induction of genes encoding enzyme and nuclear receptors involved in regulating nutrient metabolism in the liver. In this manner, bile acids function as nutrient signaling molecules in the liver to regulate metabolism. Model for the role of sphingosine 1-phosphate receptor 2 in regulating nutrient metabolism in the liver. Abbreviations: S1PR2, sphingosine-1-phosphate receptor 2; TCA, taurocholate; Src, Src kinase; EGFR, epidermal growth factor receptor; PI3K, phosphoinositide-3-kinase; PKCζ, protein kinase C zeta; PPARα, peroxisome proliferator-activated receptor alpha; FXR, farnesoid X receptor; SHP, short heterodimeric partner; NTCP, Na þ /taurocholate co-transporting polypeptide; BSEP, bile salt export pump; PC, phosphotidylcholine; PEPCK, phosphoenolpyruvate carboxykinase; G-6-Pase, glucose-6-phosphatase; PDK1, phosphoinositide-dependent protein kinase 1; AKT, protein kinase B; SREBP, sterol regulatory element-binding protein.
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